Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors

• Main Authors: Adriano Mollica (Author), Sveva Pelliccia (Author), Valeria Famiglini (Author), Azzurra Stefanucci (Author), Giorgia Macedonio (Author), Annalisa Chiavaroli (Author), Giustino Orlando (Author), Luigi Brunetti (Author), Claudio Ferrante (Author), Stefano Pieretti (Author), Ettore Novellino (Author), Sandor Benyhe (Author), Ferenc Zador (Author), Anna Erdei (Author), Edina Szucs (Author), Reza Samavati (Author), Szabolcs Dvorácskó (Author), Csaba Tomboly (Author), Rino Ragno (Author), Alexandros Patsilinakos (Author), Romano Silvestri (Author)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2017-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of µ-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these s...